Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus
Executive Summary
ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.
You may also be interested in...
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
Merck Spin-Off Prexton Turns mGluR4 Fortunes Around In Parkinson's Disease
Prexton Therapeutics has the only mGluR4-targeting drug candidate in clinical testing, after a number of big pharma dropped preclinical programs. The company has just secured €29m to fund two Phase II trials.
Achilles Therapeutics Targets The Root Of Cancer
Emerging Company Profile: With funding from Cancer Research UK and Syncona – and a wealth of science from its founders – newly launched London-based immuno-oncology company Achilles Therapeutics, believes it has identified cancer's weak spot.